newsfilter
← Latest News
GlobeNewswire·

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues pre-launch medical